Literature DB >> 32763452

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

O Michielin1, A van Akkooi2, P Lorigan3, P A Ascierto4, R Dummer5, C Robert6, A Arance7, C U Blank8, V Chiarion Sileni9, M Donia10, M B Faries11, C Gaudy-Marqueste12, H Gogas13, J J Grob12, M Guckenberger14, J Haanen8, A J Hayes15, C Hoeller16, C Lebbé17, I Lugowska18, M Mandalà19, I Márquez-Rodas20, P Nathan21, B Neyns22, R Olofsson Bagge23, S Puig24, P Rutkowski25, B Schilling26, V K Sondak27, H Tawbi28, A Testori29, U Keilholz30.   

Abstract

The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. The aim of the conference was to develop recommendations on topics that are not covered in detail in the current ESMO Clinical Practice Guideline and where available evidence is either limited or conflicting. The main topics identified for discussion were: (i) the management of locoregional disease; (ii) targeted versus immunotherapies in the adjuvant setting; (iii) targeted versus immunotherapies for the first-line treatment of metastatic melanoma; (iv) when to stop immunotherapy or targeted therapy in the metastatic setting; and (v) systemic versus local treatment of brain metastases. The expert panel was divided into five working groups in order to each address questions relating to one of the five topics outlined above. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the results relating to the management of locoregional melanoma, including findings from the expert panel discussions, consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adjuvant; consensus; immunotherapy; melanoma; targeted therapy; treatment

Mesh:

Year:  2020        PMID: 32763452     DOI: 10.1016/j.annonc.2020.07.005

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  12 in total

Review 1.  Electroporation and Immunotherapy-Unleashing the Abscopal Effect.

Authors:  Tobias Freyberg Justesen; Adile Orhan; Hans Raskov; Christian Nolsoe; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

2.  Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist.

Authors:  Yongjie Yang; Yanfang Ma; Jingli Lu; Qiwen Zhang; Kelei Guan; Kefeng Liu; Jian Kang; Shuzhang Du; Shu Tang; Xuehui Liu; Ailing Zhang; Dirk Schadendorf; Sanjiv S Agarwala; Xiaojian Zhang
Journal:  Ann Transl Med       Date:  2021-07

3.  Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Authors:  Paweł Rogala; Anna M Czarnecka; Bożena Cybulska-Stopa; Krzysztof Ostaszewski; Karolina Piejko; Marcin Ziętek; Robert Dziura; Ewa Rutkowska; Łukasz Galus; Natasza Kempa-Kamińska; Joanna Seredyńska; Wiesław Bal; Katarzyna Kozak; Anna Surus-Hyla; Tomasz Kubiatowski; Grażyna Kamińska-Winciorek; Rafał Suwiński; Jacek Mackiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

Review 4.  Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.

Authors:  Claudia Trojaniello; Jason J Luke; Paolo A Ascierto
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

Review 5.  Molecular Aspects of the Isolated Limb Infusion Procedure.

Authors:  Jüri Teras; Michael J Carr; Jonathan S Zager; Hidde M Kroon
Journal:  Biomedicines       Date:  2021-02-07

Review 6.  Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool.

Authors:  C Jacklin; M Tan; S Sravanam; C J Harrison
Journal:  JPRAS Open       Date:  2021-12-08

Review 7.  Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results.

Authors:  Alessandro Comandone; Federica Vana; Tiziana Comandone; Marcello Tucci
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

8.  Does the pattern of lymphatic drainage influence the risk of nodal recurrence in trunk melanoma patients with negative sentinel lymph node biopsy?

Authors:  Francisca Jácome Morgado; Paula Soeiro; Ana Brinca; André Pinho; Ricardo Vieira
Journal:  An Bras Dermatol       Date:  2021-10-05       Impact factor: 1.896

9.  The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma.

Authors:  Paweł Sobczuk; Katarzyna Kozak; Sylwia Kopeć; Paweł Rogala; Tomasz Świtaj; Hanna Koseła-Paterczyk; Aleksandra Gos; Andrzej Tysarowski; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

10.  Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.

Authors:  Georg Lodde; Andrea Forschner; Jessica Hassel; Lena M Wulfken; Friedegund Meier; Peter Mohr; Katharina Kähler; Bastian Schilling; Carmen Loquai; Carola Berking; Svea Hüning; Kerstin Schatton; Christoffer Gebhardt; Julia Eckardt; Ralf Gutzmer; Lydia Reinhardt; Valerie Glutsch; Ulrike Nikfarjam; Michael Erdmann; Andreas Stang; Bernd Kowall; Alexander Roesch; Selma Ugurel; Lisa Zimmer; Dirk Schadendorf; Elisabeth Livingstone
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.